Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria
Layering all three organ-protective drug classes — an SGLT2 inhibitor, a GLP-1 receptor agonist, and finerenone — on top of standard care could add roughly 3 extra years free of major heart events and more than 5 years free of kidney-disease progression for a 50-year-old with type 2 diabetes and albuminuria.
Background
SGLT2 inhibitors, GLP-1 receptor agonists, and the nonsteroidal mineralocorticoid receptor antagonist finerenone each independently reduce cardiovascular, kidney, and mortality outcomes in type 2 diabetes with albuminuria, but the combined lifetime benefit of using all three together had not been quantified.
Study design
Investigators pooled treatment effects from two SGLT2 inhibitor trials (CANVAS, CREDENCE), two finerenone trials (FIDELIO-DKD, FIGARO-DKD), and eight GLP-1 receptor agonist trials, then applied actuarial methods to estimate absolute and lifetime benefits of combination therapy versus conventional care (renin-angiotensin system blockade plus traditional risk-factor control).
Key findings
Combination therapy was associated with a hazard ratio of 0.65 (95% CI 0.55-0.76) for major adverse cardiovascular events. For a 50-year-old starting treatment, projected MACE-free survival rose from 17.9 to 21.1 years (3.2 years gained), with further gains of 3.2 years free of heart-failure hospitalization, 5.5 years free of CKD progression, and 2.4 years of overall survival.
Clinical implications
The analysis supports early, layered use of all three drug classes rather than one-at-a-time escalation in albuminuric type 2 diabetes. Benefits are modeled estimates rather than head-to-head trial results, but remained clinically meaningful even under a conservative assumption of only 50% additive effect.
Category
Research
Source
Circulation
More from ASNRT News
Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.